In this review, we will focus on Part 1A, which randomized 1189 patients with PD-L1 ≥ 1% WT stage IV NSCLC to either nivolumab, 3 mg/kg every two weeks with ipilimumab 1 mg/kg every six weeks, nivolumab, 240 mg every two weeks, or platinum doublet for four cycles [24]. Here, CD274 is linked to non-small cell lung carcinoma.